GO
Loading...

Sanofi SA

More

  • After-Hours Buzz: LTD, GILD & More Monday, 10 Dec 2012 | 5:10 PM ET

    Check out which companies are making headlines after the bell Monday.

  • European Stocks Close Mixed as 'Cliff' Concerns Weigh Tuesday, 4 Dec 2012 | 11:51 AM ET

    European shares ended mixed Tuesday amid "fiscal cliff" discussions in the U.S., but losses were limited as EU finance ministers met in Brussels to discuss details of a possible banking union.

  • *Amgen shares rise 1.4 percent. LOS ANGELES, Nov 6- Amgen Inc's experimental cholesterol-lowering drug, AMG145, reduced levels of ``bad'' cholesterol up to 66 percent in patients already taking statin drugs, according to results from a mid-stage trial that were presented on Tuesday.

  • UPDATE 1-Europe approves high-price gene therapy Friday, 2 Nov 2012 | 10:43 AM ET

    *European Commission clears Glybera for ultra rare disease. The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros per patient, a new record for pricey modern medicines.

  • Medidata jumps after announcing Sanofi contract Wednesday, 31 Oct 2012 | 4:23 PM ET

    NEW YORK-- Shares of Medidata Solutions Inc. climbed Wednesday after the research software maker said it won a contract with French drugmaker Sanofi. The companies said Sanofi will use Medidata's "cloud" technology to collect and manage clinical data for its entire research and development organization.

  • UPDATE 1-Strong refining margins boost Total Q3 Wednesday, 31 Oct 2012 | 8:01 AM ET

    PARIS, Oct 31- French oil company Total reported a 20 percent rise in third-quarter net adjusted profit to 3.348 billion euros on Wednesday, beating analysts' expectations thanks to a sharp increase in refining margins.

  • Sanofi: Moving Outside of the BRICS     Sunday, 28 Oct 2012 | 9:35 PM ET

    Christopher Viehbacher, CEO, Sanofi says that as cost rises, the firm is growing its emerging-markets business outside of the BRIC nations.

  • ImmunoGen takes wider 1st-qtr loss as costs grow Friday, 26 Oct 2012 | 8:59 AM ET

    WALTHAM, Mass.-- ImmunoGen Inc. on Friday said that its fiscal first quarter loss widened 29 percent, as it spent more money developing its experimental drugs.

  • Sanofi CEO on Orphan Drugs     Thursday, 25 Oct 2012 | 6:25 PM ET

    Sanofi CEO Chris Viehbacher offers insight on quarterly earnings, his plans for the company going forward, growth in emerging markets, and the orphan drugs boom.

  • News Summary: Sanofi profit slumps in 3rd quarter Thursday, 25 Oct 2012 | 2:29 PM ET

    SHRINKING PROFIT: Sanofi saw its earnings slump in the third quarter as generic competitors ate into profits of its Eloxatin cancer treatment. DETAILS: Sanofi earned 1.6 billion for the July-September quarter, down 20 percent from 2 billion a year earlier.

  • Regeneron posts strong 3Q results on new approvals Wednesday, 24 Oct 2012 | 9:50 AM ET

    TARRYTOWN, N.Y.-- Regeneron Pharmaceuticals Inc. on Wednesday reported third-quarter results that far exceeded Wall Street expectations as it won key new approvals for its eye drug Eylea and cancer drug Zaltrap.

  • Isis Pharma gets $1.1M payment from Alnylam Tuesday, 23 Oct 2012 | 4:02 PM ET

    NEW YORK-- Isis Pharmaceuticals Inc. said Tuesday that it will get $1.1 million from Alnylam Pharmaceuticals Inc. as part of Alnylam's new collaboration with Genzyme.

  • ISIS shares up after positive FDA panel review Friday, 19 Oct 2012 | 9:24 AM ET

    The FDA is not required to follow the committee's advice, though it often does. In its review posted ahead of the meeting, the FDA said Kynamro was linked to both benign and cancerous tumors. Jefferies analyst Eun Yang expects "very limited use of Kynamro if approved," due to the safety concerns brought up at the FDA meeting.

  • Isis trading halts as FDA reviews key drug's risks Thursday, 18 Oct 2012 | 12:58 AM ET

    Drug developer Isis Pharmaceuticals Inc. and partner Genzyme said Thursday a panel of advisers to the Food and Drug Administration had voted 9 to 6 to recommend approval of Kynamro, for treating patients genetically predisposed to have sky-high LDL, or bad cholesterol. The FDA is not bound to follow recommendations of its advisers, but usually does so.

  • News Summary: Coca-Cola, Sanofi partner on drinks Tuesday, 16 Oct 2012 | 8:05 PM ET

    DRINK UP: The Coca-Cola Co. and drug maker Sanofi are partnering to launch a line of "beauty drinks" in France. SMALL TEST: Coca-Cola declined to give details but said in a statement that the drinks will be sold in a "small scale pilot" limited to a number of pharmacies in the country.

  • Coca-Cola to launch 'beauty drinks' in France Tuesday, 16 Oct 2012 | 3:42 PM ET

    NEW YORK-- The Coca-Cola Co. and Sanofi are partnering to launch a line of "beauty drinks" in France. The Coca-Cola business unit in France said in a statement that the drinks will be sold in a "small scale pilot" limited to a number of pharmacies in the country.

  • Isis Pharma tumbles on Kynamro cancer concerns Tuesday, 16 Oct 2012 | 1:34 PM ET

    NEW YORK-- Shares of Isis Pharmaceuticals Inc. skidded Tuesday as regulators raised questions about links between the company's experimental cholesterol drug Kynamro and cancer. THE SPARK: Isis and its partner Genzyme will discuss Kynamro with a Food and Drug Administration advisory panel on Thursday.

  • Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic Avaproï¿ ½ receives FDA approval. *Irbesartan tablets USP is the generic equivalent to Sanofi's Avaproï¿ ½.

  • Sanofi's Genzyme says making progress with MS drugs Friday, 12 Oct 2012 | 9:38 AM ET

    LYON, Oct 12- Sanofi's Genzyme unit has received positive feedback from U.S. doctors after the recent launch of multiple sclerosis pill Aubagio and moving toward refiling its FDA application for MS drug Lemtrada, senior executives said on Friday.

  • Sector Wrap: Diabetes drug makers Thursday, 11 Oct 2012 | 5:00 PM ET

    NEW YORK-- A Jefferies& Co. analyst said Thursday that sales of diabetes drugs should keep growing at a strong clip for the rest of the decade, reaching $65 billion a year in 2020.. He said Eli Lilly and Co. should surpass France's Sanofi as the second-largest diabetes drug seller.